ALA 001
Alternative Names: ALA-001Latest Information Update: 21 Mar 2022
At a glance
- Originator PharmAla Biotech
- Developer InterVivo Solutions; PharmAla Biotech
- Class Amines; Amphetamines; Benzodioxoles
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Unspecified
Most Recent Events
- 21 Mar 2022 PharamaALa plans for Pre-IND meeting with international regulators to present findings for ALA 001 (PharmaAla website, March 2022)
- 21 Mar 2022 PharamaALa plans for Pre-IND meeting with FDA to present findings for ALA 001 (PharmaAla website, March 2022)
- 07 Mar 2022 PharmaAla has patents pending for Novel MDMA entities in Canada (PharmaAla website, March 2022)